Document Type
Article
Publication Date
7-16-2019
Abstract
Clinical management of asthma and chronic obstructive pulmonary disease (COPD) has primarily relied on the use of beta 2 adrenergic receptor agonists (bronchodilators) and corticosteroids, and more recently, monoclonal antibody therapies (biologics) targeting specific cytokines and their functions. Although these approaches provide relief from exacerbations, questions remain on their long-term efficacy and safety. Furthermore, current therapeutics do not address progressive airway remodeling (AR), a key pathological feature of severe obstructive lung disease. Strikingly, agonists of the bitter taste receptors (TAS2Rs) deliver robust bronchodilation, curtail allergen-induced inflammatory responses in the airways and regulate airway smooth muscle (ASM) cell proliferation and mitigate features of AR
Recommended Citation
Nayak, Ajay P.; Shah, Sushrut D.; Michael, James V.; and Deshpande, Deepak A., "Bitter Taste Receptors for Asthma Therapeutics." (2019). Center for Translational Medicine Faculty Papers. Paper 61.
https://jdc.jefferson.edu/transmedfp/61
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
PubMed ID
31379597
Language
English
Comments
This article has been peer reviewed. It was published in: Frontiers in Physiology.
Volume 10, Issue JUL, 2019, Article number 884.
The published version is available at DOI: 10.3389/fphys.2019.00884
Copyright © 2019 Nayak, Shah, Michael and Deshpande. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.